Lack of effect of antenatal indomethacin on fetal cerebral blood flow

B. V. Parilla, R. K. Tamura, L. S. Cohen, E. Clark, L. W. Hess, D. A. Rightmire, George Saade

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

OBJECTIVE: Our purpose was to investigate fetal cerebral blood flow and the incidence of intraventricular hemorrhage in patients undergoing tocolysis with either indomethacin or magnesium sulfate at <30 weeks' gestation. STUDY DESIGN: Consenting patients at <30 weeks' gestation with preterm labor were randomized to receive indomethacin or magnesium sulfate tocolysis. Magnesium sulfate was administered intravenously with an 8 gm loading dose given over the first hour, 4 gm over the second hour, and then a maintenance infusion of 2.5 gm per hour. The infusion was continued for approximately 12 hours after the cessation of uterine contractions. Patients randomized to receive indomethacin were given an initial dose of 50 to 100 mg orally or per rectum, followed by 25 to 50 mg orally every 4 to 6 hours for 24 to 48 hours. Oral tocolytic agents were not used after successful tocolysis. Betamethasone was administered to all patients. Patients underwent fetal cerebral Doppler studies during tocolytic therapy and at least 24 hours after completion of the treatment. RESULTS: Twelve patients were randomized to receive indomethacin and twelve patients were randomized to receive magnesium sulfate. Twenty-one fetuses underwent cerebral Doppler studies in triplicate during and after therapy. The mean gestational age at tocolysis was 27.5 ± 1.9 weeks for the indomethacin group and 26.4 ± 1.6 weeks for the magnesium sulfate group (p = 0.14). The middle cerebral artery resistance index for fetuses during indomethacin treatment was 0.73 ± 0.09, whereas the resistance index after therapy was 0.75 ± 0.05 (p = 0.49). The resistance index during magnesium sulfate tocolysis was 0.79 ± 0.04 and after therapy it was 0.76 ± 0.04 (p = 0.18). There was no significant difference in the resistance index between the groups on or off therapy. In addition, the incidence of intraventricular hemorrhage was similar in both groups. CONCLUSION: These results suggest that indomethacin does not significantly affect fetal cerebral blood flow. If antenatal indomethacin in the preterm fetus increases the risk of intraventricular hemorrhage, it would appear to be by another mechanism.

Original languageEnglish (US)
Pages (from-to)1166-1171
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume176
Issue number6
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Cerebrovascular Circulation
Tocolysis
Fetal Blood
Indomethacin
Magnesium Sulfate
Fetus
Hemorrhage
Therapeutics
Tocolytic Agents
Betamethasone
Uterine Contraction
Pregnancy
Premature Obstetric Labor
Incidence
Middle Cerebral Artery
Rectum
Gestational Age
Maintenance

Keywords

  • Fetal cerebral blood flow
  • Indomethacin
  • Intraventicular hemmorhage

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Parilla, B. V., Tamura, R. K., Cohen, L. S., Clark, E., Hess, L. W., Rightmire, D. A., & Saade, G. (1997). Lack of effect of antenatal indomethacin on fetal cerebral blood flow. American Journal of Obstetrics and Gynecology, 176(6), 1166-1171. https://doi.org/10.1016/S0002-9378(97)70330-2

Lack of effect of antenatal indomethacin on fetal cerebral blood flow. / Parilla, B. V.; Tamura, R. K.; Cohen, L. S.; Clark, E.; Hess, L. W.; Rightmire, D. A.; Saade, George.

In: American Journal of Obstetrics and Gynecology, Vol. 176, No. 6, 1997, p. 1166-1171.

Research output: Contribution to journalArticle

Parilla, BV, Tamura, RK, Cohen, LS, Clark, E, Hess, LW, Rightmire, DA & Saade, G 1997, 'Lack of effect of antenatal indomethacin on fetal cerebral blood flow', American Journal of Obstetrics and Gynecology, vol. 176, no. 6, pp. 1166-1171. https://doi.org/10.1016/S0002-9378(97)70330-2
Parilla, B. V. ; Tamura, R. K. ; Cohen, L. S. ; Clark, E. ; Hess, L. W. ; Rightmire, D. A. ; Saade, George. / Lack of effect of antenatal indomethacin on fetal cerebral blood flow. In: American Journal of Obstetrics and Gynecology. 1997 ; Vol. 176, No. 6. pp. 1166-1171.
@article{cf1ef4dc13d4498cb91635d2e921cd30,
title = "Lack of effect of antenatal indomethacin on fetal cerebral blood flow",
abstract = "OBJECTIVE: Our purpose was to investigate fetal cerebral blood flow and the incidence of intraventricular hemorrhage in patients undergoing tocolysis with either indomethacin or magnesium sulfate at <30 weeks' gestation. STUDY DESIGN: Consenting patients at <30 weeks' gestation with preterm labor were randomized to receive indomethacin or magnesium sulfate tocolysis. Magnesium sulfate was administered intravenously with an 8 gm loading dose given over the first hour, 4 gm over the second hour, and then a maintenance infusion of 2.5 gm per hour. The infusion was continued for approximately 12 hours after the cessation of uterine contractions. Patients randomized to receive indomethacin were given an initial dose of 50 to 100 mg orally or per rectum, followed by 25 to 50 mg orally every 4 to 6 hours for 24 to 48 hours. Oral tocolytic agents were not used after successful tocolysis. Betamethasone was administered to all patients. Patients underwent fetal cerebral Doppler studies during tocolytic therapy and at least 24 hours after completion of the treatment. RESULTS: Twelve patients were randomized to receive indomethacin and twelve patients were randomized to receive magnesium sulfate. Twenty-one fetuses underwent cerebral Doppler studies in triplicate during and after therapy. The mean gestational age at tocolysis was 27.5 ± 1.9 weeks for the indomethacin group and 26.4 ± 1.6 weeks for the magnesium sulfate group (p = 0.14). The middle cerebral artery resistance index for fetuses during indomethacin treatment was 0.73 ± 0.09, whereas the resistance index after therapy was 0.75 ± 0.05 (p = 0.49). The resistance index during magnesium sulfate tocolysis was 0.79 ± 0.04 and after therapy it was 0.76 ± 0.04 (p = 0.18). There was no significant difference in the resistance index between the groups on or off therapy. In addition, the incidence of intraventricular hemorrhage was similar in both groups. CONCLUSION: These results suggest that indomethacin does not significantly affect fetal cerebral blood flow. If antenatal indomethacin in the preterm fetus increases the risk of intraventricular hemorrhage, it would appear to be by another mechanism.",
keywords = "Fetal cerebral blood flow, Indomethacin, Intraventicular hemmorhage",
author = "Parilla, {B. V.} and Tamura, {R. K.} and Cohen, {L. S.} and E. Clark and Hess, {L. W.} and Rightmire, {D. A.} and George Saade",
year = "1997",
doi = "10.1016/S0002-9378(97)70330-2",
language = "English (US)",
volume = "176",
pages = "1166--1171",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Lack of effect of antenatal indomethacin on fetal cerebral blood flow

AU - Parilla, B. V.

AU - Tamura, R. K.

AU - Cohen, L. S.

AU - Clark, E.

AU - Hess, L. W.

AU - Rightmire, D. A.

AU - Saade, George

PY - 1997

Y1 - 1997

N2 - OBJECTIVE: Our purpose was to investigate fetal cerebral blood flow and the incidence of intraventricular hemorrhage in patients undergoing tocolysis with either indomethacin or magnesium sulfate at <30 weeks' gestation. STUDY DESIGN: Consenting patients at <30 weeks' gestation with preterm labor were randomized to receive indomethacin or magnesium sulfate tocolysis. Magnesium sulfate was administered intravenously with an 8 gm loading dose given over the first hour, 4 gm over the second hour, and then a maintenance infusion of 2.5 gm per hour. The infusion was continued for approximately 12 hours after the cessation of uterine contractions. Patients randomized to receive indomethacin were given an initial dose of 50 to 100 mg orally or per rectum, followed by 25 to 50 mg orally every 4 to 6 hours for 24 to 48 hours. Oral tocolytic agents were not used after successful tocolysis. Betamethasone was administered to all patients. Patients underwent fetal cerebral Doppler studies during tocolytic therapy and at least 24 hours after completion of the treatment. RESULTS: Twelve patients were randomized to receive indomethacin and twelve patients were randomized to receive magnesium sulfate. Twenty-one fetuses underwent cerebral Doppler studies in triplicate during and after therapy. The mean gestational age at tocolysis was 27.5 ± 1.9 weeks for the indomethacin group and 26.4 ± 1.6 weeks for the magnesium sulfate group (p = 0.14). The middle cerebral artery resistance index for fetuses during indomethacin treatment was 0.73 ± 0.09, whereas the resistance index after therapy was 0.75 ± 0.05 (p = 0.49). The resistance index during magnesium sulfate tocolysis was 0.79 ± 0.04 and after therapy it was 0.76 ± 0.04 (p = 0.18). There was no significant difference in the resistance index between the groups on or off therapy. In addition, the incidence of intraventricular hemorrhage was similar in both groups. CONCLUSION: These results suggest that indomethacin does not significantly affect fetal cerebral blood flow. If antenatal indomethacin in the preterm fetus increases the risk of intraventricular hemorrhage, it would appear to be by another mechanism.

AB - OBJECTIVE: Our purpose was to investigate fetal cerebral blood flow and the incidence of intraventricular hemorrhage in patients undergoing tocolysis with either indomethacin or magnesium sulfate at <30 weeks' gestation. STUDY DESIGN: Consenting patients at <30 weeks' gestation with preterm labor were randomized to receive indomethacin or magnesium sulfate tocolysis. Magnesium sulfate was administered intravenously with an 8 gm loading dose given over the first hour, 4 gm over the second hour, and then a maintenance infusion of 2.5 gm per hour. The infusion was continued for approximately 12 hours after the cessation of uterine contractions. Patients randomized to receive indomethacin were given an initial dose of 50 to 100 mg orally or per rectum, followed by 25 to 50 mg orally every 4 to 6 hours for 24 to 48 hours. Oral tocolytic agents were not used after successful tocolysis. Betamethasone was administered to all patients. Patients underwent fetal cerebral Doppler studies during tocolytic therapy and at least 24 hours after completion of the treatment. RESULTS: Twelve patients were randomized to receive indomethacin and twelve patients were randomized to receive magnesium sulfate. Twenty-one fetuses underwent cerebral Doppler studies in triplicate during and after therapy. The mean gestational age at tocolysis was 27.5 ± 1.9 weeks for the indomethacin group and 26.4 ± 1.6 weeks for the magnesium sulfate group (p = 0.14). The middle cerebral artery resistance index for fetuses during indomethacin treatment was 0.73 ± 0.09, whereas the resistance index after therapy was 0.75 ± 0.05 (p = 0.49). The resistance index during magnesium sulfate tocolysis was 0.79 ± 0.04 and after therapy it was 0.76 ± 0.04 (p = 0.18). There was no significant difference in the resistance index between the groups on or off therapy. In addition, the incidence of intraventricular hemorrhage was similar in both groups. CONCLUSION: These results suggest that indomethacin does not significantly affect fetal cerebral blood flow. If antenatal indomethacin in the preterm fetus increases the risk of intraventricular hemorrhage, it would appear to be by another mechanism.

KW - Fetal cerebral blood flow

KW - Indomethacin

KW - Intraventicular hemmorhage

UR - http://www.scopus.com/inward/record.url?scp=0030743819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030743819&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(97)70330-2

DO - 10.1016/S0002-9378(97)70330-2

M3 - Article

VL - 176

SP - 1166

EP - 1171

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -